Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.44 |
| ▸ | HTR1F | P30939 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671999 | 1.00 | CYP2D6 (0.45) | CYP2D6PKMCYP2C19OPRL1HTR1F | |
| SCHEMBL5669532 | 0.89 | OPRL1 (0.42) | CYP2D6PKMCYP2C19OPRL1GRM5 | |
| SCHEMBL5669537 | 0.89 | OPRL1 (0.42) | CYP2D6PKMCYP2C19OPRL1GRM5 | |
| SCHEMBL5671796 | 0.89 | OPRL1 (0.43) | CYP2D6PKMCYP2C19OPRL1GRM5 | |
| SCHEMBL5670590 | 0.87 | OPRL1 (0.44) | CYP2D6PKMCYP2C19OPRL1GRM5 | |
| SCHEMBL5670588 | 0.87 | OPRL1 (0.44) | CYP2D6PKMCYP2C19OPRL1GRM5 | |
| SCHEMBL5669746 | 0.80 | GRM5 (0.37) | GRM5MC4RADAM10PTGDR2 | |
| SCHEMBL5669744 | 0.80 | GRM5 (0.37) | GRM5MC4RADAM10PTGDR2 | |
| SCHEMBL5669290 | 0.78 | STS (0.44) | MC4R | |
| SCHEMBL5669289 | 0.78 | STS (0.44) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | CYP2D6 2584/4885PKM 4604/4885CYP2C19 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.